Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA101 plus bendamustine versus bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma
NL-OMON47138Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of obinutuzumab and bendamustine, sponsored by Roche. Started Sep 2011; status: active, not recruiting.
02
Drugs
obinutuzumabbendamustine
Beyond the preview
Go deeper on NL-OMON47138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47138.